%0 Journal Article
%A Marquez-Rodas, Ivan
%A Alvarez, Ana
%A Arance, Ana
%A Valduvieco, Izaskun
%A Berciano-Guerrero, Miguel-angel
%A Delgado, Raquel
%A Soria, Ainara
%A Lopez-Campos, Fernando
%A Sanchez, Pedro
%A Romero, Jose Luis
%A Martin-Liberal, Juan
%A Lucas, Anna
%A Diaz-Beveridge, Roberto
%A Conde-Moreno, Antonio-Jose
%A Alamo-de-la-Gala, Maria del Carmen
%A Garcia-Castano, Almudena
%A Prada, Pedro Jose
%A Gonzalez-Cao, Maria
%A Puertas, Enrique
%A Vidal, Joana
%A Foro, Palmira
%A Aguado-de-la-Rosa, Carlos
%A Corona, Juan Antonio
%A Cerezuela-Fuentes, Pablo
%A Lopez, Paco
%A Luna, Pablo
%A Aymar, Neus
%A Puertolas, Teresa
%A Sanagustin, Pilar
%A Berrocal, Alfonso
%T Encorafenib and binimetinib followed by radiotherapy for patients with BRAF<SUP>V600</SUP>-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
%D 2024
%@ 1522-8517
%U https://hdl.handle.net/10668/28507
%X Background. Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAF(V600)-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAF(V600)-mutant melanoma and brain metastasis (BM) and explored if radiotherapy improves the duration of response. Methods. E-BRAIN/GEM1802 was a prospective, multicenter, single-arm, phase II trial that enrolled patients with melanoma BRAF(V600)-mutant and BM. Patients received encorafenib 450 mg once daily plus binimetinib 45 mg BID, and those who achieved a partial response or stable disease at first tumor assessment were offered radiotherapy. Treatment continued until progression. Primary endpoint was intracranial response rate (icRR) after 2 months of EB, establishing a futility threshold of 60%. Results. The study included 25 patients with no BM symptoms and 23 patients with BM symptoms regardless of using corticosteroids. Among them, 31 patients (64.6%) received sequential radiotherapy. After 2 months, icRR was 70.8% (95% CI: 55.9-83.1); 10.4% complete response. Median intracranial progression-free survival (PFS) and OS were 8.5 (95% CI: 6.4-11.8) and 15.9 (95% CI: 10.7-21.4) months, respectively (8.3 months for icPFS and 13.9 months OS for patients receiving RDT). Most common grades 3-4 treatment-related adverse event was alanine aminotransferase (ALT) increased (10.4%). Conclusions. Encorafenib plus binimetinib showed promising clinical benefit in terms of icRR, and tolerable safety profile with low frequency of high-grade TRAEs, in patients with BRAFV600-mutant melanoma and BM, including those with symptoms and need for steroids. Sequential radiotherapy is feasible but it does not seem to prolong response.
%K Brain metastasis
%K Encorafenib and binimetinib
%K Melanoma
%K Radiotherapy
%K Targeted therapy
%~